E-LIB Suche - Ergebnisse für: Akira Koibuchi

1

Clinical Pharmacology of the Antibody–Drug Conjugate Enfort..:

Tang, Mei ; Garg, Amit ; Bonate, Peter L....
Clinical Pharmacokinetics. 63 (2024) 4 - p. 423-438 , 2024

2

Single‐ and Multiple‐dose Safety, Tolerability, Pharmacokin..:

Taniuchi, Yuta ; van Till, J. W. Olivier ; Wojtkowski, Tomasz...
Clinical Pharmacology in Drug Development. 12 (2023) 8 - p. 810-818 , 2023

Link: https://doi.org/10.1002/..

3

A State-of-the-Art Roadmap for Biomarker-Driven Drug Develo..:

Serelli-Lee, Victoria ; Ito, Kazumi ; Koibuchi, Akira...
Journal of Personalized Medicine. 12 (2022) 5 - p. 669 , 2022

Link: https://doi.org/10.3390/..

4

Single‐ and multiple‐dose safety, tolerability, pharmacokin..:

Ito, Mototsugu ; Tauscher‐Wisniewski, Sitra ; Smulders, Ronald A....
Muscle & Nerve. 65 (2021) 1 - p. 110-120 , 2021

Link: https://doi.org/10.1002/..

5

Development of a New Conditionally Immortalized Human Liver..:

Zhu, Meiyan ; Koibuchi, Akira ; Ide, Hideyuki...
Biological and Pharmaceutical Bulletin. 41 (2018) 3 - p. 440-444 , 2018

Link: https://doi.org/10.1248/..

6

A new immortalized human liver sinusoidal endothelial cell ..:

Zhu, Meiyan ; Furihata, Tomomi ; Koibuchi, Akira...
Drug Metabolism and Pharmacokinetics. 32 (2017) 1 - p. S70 , 2017

Link: https://doi.org/10.1016/..

7

Characterization of release profile of ornithine carbamoylt..:

Furihata, Tomomi ; Aizawa, Takayuki ; Koibuchi, Akira...
Drug Metabolism and Pharmacokinetics. 31 (2016) 1 - p. 102-105 , 2016

Link: https://doi.org/10.1016/..

8

A State-of-the-Art Roadmap for Biomarker-Driven Drug Develo..:

Victoria Serelli-Lee ; Kazumi Ito ; Akira Koibuchi...
https://www.mdpi.com/2075-4426/12/5/669. , 2022

Link: https://doi.org/10.3390/..

9

A State-of-the-Art Roadmap for Biomarker-Driven Drug Develo..:

Victoria Serelli-Lee ; Kazumi Ito ; Akira Koibuchi...
https://dx.doi.org/10.3390/jpm12050669. , 2022

Link: https://doi.org/10.3390/..

10

A State-of-the-Art Roadmap for Biomarker-Driven Drug Develo..:

Serelli-Lee, Victoria ; Ito, Kazumi ; Koibuchi, Akira...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143954/. , 2022

Link: http://www.ncbi.nlm.nih...

11

Single‐ and multiple‐dose safety, tolerability, pharmacokin..:

Ito, Mototsugu ; Tauscher‐Wisniewski, Sitra ; Smulders, Ronald A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298414/. , 2021

Link: http://www.ncbi.nlm.nih...

12

Utility of human epidermal growth factor 2 heterogeneity as..:

Narusawa, Eriko ; Kurozumi, Sasagu ; Katayama, Ayaka...
Medical Molecular Morphology. , 2024

Link: https://doi.org/10.1007/..

13

GH-induced LH hyporesponsiveness as a potential mechanism f..:

Nishio, Rie ; Takeshita, Akira ; Uchida, Toyoyoshi...
Endocrine Journal. 68 (2021) 8 - p. 953-968 , 2021

Link: https://doi.org/10.1507/..

14

The prevalence of opportunistic infections and malignancies..:

Katano, Harutaka ; Hishima, Tsunekazu ; Mochizuki, Makoto...
BMC Infectious Diseases. 14 (2014) 1 - p. , 2014

Link: https://doi.org/10.1186/..

15

Interaction of silencing mediator for retinoid and thyroid ..:

Hirooka-Masui, Kazumi ; Lesmana, Ronny ; Iwasaki, Toshiharu...
Life Sciences. 92 (2013) 17-19 - p. 911-915 , 2013

Link: https://doi.org/10.1016/..